GPR65 and neoplasm: Preclinical studies have further substantiated this finding, showing that the genetic deletion of GPR65 in murine tumour models or pharmacological inhibition with selective small-molecule GPR65 antagonists developed by Pathios counteracts low-pH-induced immunosuppressive macrophage polarisation, restores anti-tumour immune activity, enhances infiltration of cytotoxic effector cells, and synergises with the anti-PD-1 checkpoint blockade to suppress tumour growth in syngeneic models [66,67,123].